Sanofi raises profit outlook after strong second quarter
French drugmaker posts nearly €9bn in revenue for the quarter
29 July 2021 - 18:05
byMatthias Blamont
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Paris — Sanofi raised its 2021 profit forecast on Thursday after its vaccines and star eczema treatment helped it beat second-quarter results expectations.
The French drugmaker said it was now targeting earnings per share growth of about 12% at constant exchange rates in 2021, up from “high single digit” percentage growth previously.
Sanofi, which shocked investors in 2020 with a delay to a Covid-19 vaccine it is developing with Britain’s GlaxoSmithKline , reiterated its confidence in the shot, which it hopes will secure regulatory approval by the end of the year.
Europe’s drug regulator said last week it had started a real-time review of the vaccine.
If approved, Sanofi’s shot will come long after ones from Pfizer/BioNTech, and Moderna, which have produced efficacy results of more than 90%.
But the French company believes its vaccine could play a significant role in tackling the pandemic, as many parts of the world still have a pressing need for doses.
In countries already rolling out mass vaccinations, Sanofi also sees a potential role for the shot as a booster, as many regulators contemplate recommending a third dose to extend protection.
So far, Sanofi has purchasing agreements with the US, the EU, Britain and Canada, as well as with the World Health Organization-backed Covax facility.
The company has also pledged to help other Covid-19 vaccine makers in 2021, striking “fill and finish” deals for shots made by Pfizer/BioNTech, Moderna and Johnson & Johnson.
Sales of Dupixent, which is sold to patients with eczema but also prescribed for other conditions such as asthma, jumped 57% to €1.24bn.
Revenue at the vaccines unit was up 16.2% to €1bn, helped by stronger demand for booster and meningitis shots.
Overall, Sanofi’s sales rose 12.4% in the second quarter to €8.74bn, while business net income — a figure the company uses as its core metric to measure profits — was up 16.8% to €1.73bn.
Analysts polled by Refinitiv had on average been expecting sales of €8.5bn and net income of €1bn.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Sanofi raises profit outlook after strong second quarter
French drugmaker posts nearly €9bn in revenue for the quarter
Paris — Sanofi raised its 2021 profit forecast on Thursday after its vaccines and star eczema treatment helped it beat second-quarter results expectations.
The French drugmaker said it was now targeting earnings per share growth of about 12% at constant exchange rates in 2021, up from “high single digit” percentage growth previously.
Sanofi, which shocked investors in 2020 with a delay to a Covid-19 vaccine it is developing with Britain’s GlaxoSmithKline , reiterated its confidence in the shot, which it hopes will secure regulatory approval by the end of the year.
Europe’s drug regulator said last week it had started a real-time review of the vaccine.
If approved, Sanofi’s shot will come long after ones from Pfizer/BioNTech, and Moderna, which have produced efficacy results of more than 90%.
But the French company believes its vaccine could play a significant role in tackling the pandemic, as many parts of the world still have a pressing need for doses.
In countries already rolling out mass vaccinations, Sanofi also sees a potential role for the shot as a booster, as many regulators contemplate recommending a third dose to extend protection.
So far, Sanofi has purchasing agreements with the US, the EU, Britain and Canada, as well as with the World Health Organization-backed Covax facility.
The company has also pledged to help other Covid-19 vaccine makers in 2021, striking “fill and finish” deals for shots made by Pfizer/BioNTech, Moderna and Johnson & Johnson.
Sales of Dupixent, which is sold to patients with eczema but also prescribed for other conditions such as asthma, jumped 57% to €1.24bn.
Revenue at the vaccines unit was up 16.2% to €1bn, helped by stronger demand for booster and meningitis shots.
Overall, Sanofi’s sales rose 12.4% in the second quarter to €8.74bn, while business net income — a figure the company uses as its core metric to measure profits — was up 16.8% to €1.73bn.
Analysts polled by Refinitiv had on average been expecting sales of €8.5bn and net income of €1bn.
Reuters
Covid-19 vaccine set to be one of Pfizer’s all-time best sellers
Hot stock Moderna joins S&P as most heavily traded company in 2021
Ascendis inks R770m deal to sell its animal-health division
Panacea Biotec jumps on manufacturing licence for Sputnik V vaccine
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Shot in the arm for Africa vaccine output as Aspen gets R10bn
GSK unveils £8bn boost from consumer unit spin-off
J&J settles New York opioid suits with $263m payment before US jury trial
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.